Cytodyn Inc (CYDY)

[JPG77]

I like the way that he summarizes the article"

CYDY is undergoing an extreme metamorphosis into “CytoDyn 2.0” as coined by Dr. Pestell during the call. Investors are choosing to look at having to do another monotherapy trial as negative when in fact it likely accelerates the process and the new data from CD03 monotherapy trial might lead to a breakthrough therapy designation. Instead of dwelling on past financings that led to dilution, investors should be looking at the licensing opportunities that seem imminent. If investors were to simply look at this company under a new lens as a platform technology that is assured revenue via a diagnostic in prostate cancer, as a phase 2 cancer company with 2 “shovel ready” indications, and a greater than 90% chance of approval as a monotherapy in HIV, they would see that a $150 million market cap based on 248 million shares outstanding is just too low.